Stocks TelegraphStocks Telegraph
Stock Ideas

CRSP Financial Statements and Analysis

NASDAQ : CRSP

CRISPR Therapeutics AG

$41.35
0.8611+2.13%
Open: 9:52 AM
73.92
BESG ScoreESG Rating

CRSP FINANCIAL STATEMENTS

An instrumental part of fundamental analysis is measuring key indicators of an asset, which are the factors that can influence its value and price. However, sometimes investors show more interest in financial statements with other factors to determine whether investing in that company is the right decision. Financial statements of a company include:

  • Balance Sheet
  • Income Statement
  • Cash Flow Statement

CRSP Income Statement

A company's income statement helps investors and business owners determine whether the company is profitable or losing money. Profitability is a key factor investors consider before investing in a stock. Income statements provide them with information about a company's profitability over time. The statement also enables them to observe trends in company spending and earnings since it breaks down individual costs and revenues. Income statements also provide details on where a company's money is going when it isn't profitable or its profits fluctuate.

Date2024-09-302024-06-302024-03-312023-12-312023-09-30
reported currencyUSDUSDUSDUSDUSD
calendar year20242024202420232023
periodQ3Q2Q1Q4Q3
revenue602.00K517.00K504.00K200.00M0
cost of revenue11.153M56.976M51.799M20.00M23.422M
gross profit-10.551M-56.459M-51.295M180.00M-23.422M
gross profit ratio-17.527-109.205-101.7760.900
research and development expenses82.16M75.32M71.339M95.144M90.698M
general and administrative expenses17.419M19.481M17.953M16.479M18.291M
selling and marketing expenses00000
selling general and administrative expenses17.419M19.481M17.953M16.479M18.291M
other expenses026.139M24.72M19.997M20.671M
operating expenses99.579M94.801M89.292M110.417M108.989M
cost and expenses110.732M151.777M141.091M130.417M132.411M
interest income000020.671M
interest expense00000
depreciation and amortization4.80M4.845M4.833M4.90M4.925M
ebitda-105.391M-146.415M-135.754M74.483M-132.411M
ebitda ratio-175.068-283.201-269.3530.3720
operating income-110.13M-151.26M-140.587M69.583M-132.411M
operating income ratio-182.94-292.573-278.9420.3480
total other income expenses net25.064M26.139M24.72M19.997M20.671M
income before tax-85.066M-125.121M-115.867M89.58M-111.74M
income before tax ratio-141.306-242.014-229.8950.4480
income tax expense876.00K1.287M724.00K233.00K-412.00K
net income-85.942M-126.408M-116.591M89.347M-112.152M
net income ratio-142.761-244.503-231.3310.4470
eps-1.01-1.49-1.431.12-1.41
eps diluted-1.01-1.49-1.431.10-1.41
weighted average shs out85.235M84.921M81.795M79.688M79.414M
weighted average shs out dil85.235M84.921M81.795M81.325M79.414M
Graph

CRSP Balance Sheet

Balance sheet summarizes a company's financials and can be used as a basis by investors to determine the value of a company. It shows the value of the stock, as well as the assets and liabilities of the company. A company's balance sheet displays how its assets are put to use and how those assets are financed, based on the liabilities section. Both investors and analysts analyze a company's balance sheet to determine how it allocates its resources.

Date2024-09-302024-06-302024-03-312023-12-312023-09-30
reported currencyUSDUSDUSDUSDUSD
calendar year20242024202420232023
periodQ3Q2Q1Q4Q3
cash and cash equivalents225.67M484.472M707.427M389.477M527.765M
short term investments1.71B1.517B1.401B1.304B1.212B
cash and short term investments1.936B2.002B2.108B1.694B1.74B
net receivables000200.00M0
inventory00000
other current assets8.246M8.788M11.499M14.386M20.76M
total current assets1.944B2.01B2.12B1.908B1.761B
property plant equipment net284.828M291.569M298.507M305.938M312.337M
goodwill00000
intangible assets002.00K030.00K
goodwill and intangible assets002.00K16.00K30.00K
long term investments022.736M11.516M1.973M11.83M
tax assets00-11.516M0-11.83M
other non current assets27.411M15.141M20.884M13.566M13.877M
total non current assets312.239M329.446M319.393M321.493M326.244M
other assets001.0000
total assets2.256B2.34B2.439B2.23B2.087B
account payables15.578M9.452M16.463M38.147M26.152M
short term debt33.766M32.902M15.992M15.625M15.001M
tax payables838.00K454.00K1.207M438.00K176.00K
deferred revenue4.483M4.759M4.072M4.105M3.50M
other current liabilities35.145M80.256M81.256M50.914M66.581M
total current liabilities89.81M127.823M118.99M108.791M111.234M
long term debt210.662M214.852M218.935M223.007M226.585M
deferred revenue non current12.323M12.583M13.541M14.012M15.823M
deferred tax liabilities non current00000
other non current liabilities3.677M3.646M3.615M958.00K5.394M
total non current liabilities226.662M231.081M236.091M237.977M247.802M
other liabilities00000
capital lease obligations227.545M214.852M218.935M238.632M241.586M
total liabilities316.472M358.904M355.081M346.768M359.036M
preferred stock00000
common stock2.684M2.665M2.658M2.497M2.476M
retained earnings-1.329B-1.243B-1.116B-999.70M-1.089B
accumulated other comprehensive income loss10.565M-2.879M-1.552M1.913M-6.797M
other total stockholders equity3.255B3.224B3.199B2.878B2.821B
total stockholders equity1.94B1.981B2.084B1.883B1.728B
total equity1.94B1.981B2.084B1.883B1.728B
total liabilities and stockholders equity2.256B2.34B2.439B2.23B2.087B
minority interest00000
total investments1.71B1.54B1.412B1.306B1.212B
total debt227.545M231.303M234.927M238.632M241.586M
net debt1.875M-253.169M-472.50M-150.845M-286.179M
Graph

CRSP Cash Flow

A cash flow statement is regarded as a valuable indicator of profitability and the long-term outlook for a company. It assists the company in evaluating whether it has sufficient funds to cover its expenses. Essentially, a cash flow statement represents an organization's financial health. The cash flow statement, which measures the business's ability to operate in the short as well as long term, is broken down into operating, investing, and financing activities.

Date2024-09-302024-06-302024-03-312023-12-312023-09-30
reported currencyUSDUSDUSDUSDUSD
calendar year20242024202420232023
periodQ3Q2Q1Q4Q3
deferred income tax00000
stock based compensation21.543M23.672M19.405M18.42M19.968M
change in working capital-220.98M10.49M210.49M-203.974M52.562M
accounts receivables00200.00M-200.00M70.00M
inventory0009.191M24.693M
accounts payables-38.157M9.281M9.443M-9.191M-24.693M
other working capital-2.256M1.209M1.047M-3.974M-17.438M
other non cash items173.727M15.90M-188.757M-4.766M-5.159M
net cash provided by operating activities-106.913M-95.582M109.752M-96.073M-39.856M
investments in property plant and equipment-219.00K-707.00K-721.00K-738.00K-2.118M
acquisitions net00000
purchases of investments-388.678M-475.979M-334.415M-368.149M-245.399M
sales maturities of investments247.678M349.781M237.336M287.434M369.865M
other investing activites-20.385M-126.198M-7.50M0-1.00M
net cash used for investing activites-161.604M-126.905M-97.80M-81.453M121.348M
debt repayment00000
common stock issued-305.468M-466.00K305.934M32.721M1.556M
common stock repurchased466.00K-466.00K000
dividends paid00000
other financing activites314.642M546.00K305.934M6.218M1.556M
net cash used provided by financing activities9.64M-466.00K305.934M38.939M1.556M
effect of forex changes on cash75.00K2.00K-11.00K61.00K-48.00K
net change in cash-247.282M-222.955M317.95M-138.527M83.00M
cash at end of period237.19M484.472M707.427M401.068M539.595M
cash at beginning of period484.472M707.427M389.477M539.595M456.595M
operating cashflow-106.913M-95.582M109.752M-96.073M-39.856M
capital expenditure-219.00K-707.00K-721.00K-738.00K-2.118M
free cash flow-107.132M-96.289M109.031M-96.811M-41.974M
Graph

Frequently Asked Questions

How did CRISPR Therapeutics AG do last quarter? What was its Total Revenue and Cost of Revenue?

A company's Total Revenue reveals how much money it generates before any expenses or deductions are made. As a result, this metric informs investors/stakeholders how much money the business makes. Tracking and understanding it is essential for evaluating a company's growth. As opposed to revenue, Cost of Revenue is any expenses a business incur to generate revenue. There can be high revenue in a business, but if the costs are high, it won't make a profit and will go out of business when money runs out. Therefore, CRSP generated $602.00K in revenue last quarter, while its costs came in at $11.15M.

Last quarter, how much Gross Profit did CRISPR Therapeutics AG report?

A business's Gross Profit is a key indicator of its profitability and financial performance. In other words, it reflects how efficiently a business uses labor, raw materials, and other resources. CRISPR Therapeutics AG reported a -$10.55M Gross Profit for the quarter ended Sep 30, 2024.

Have CRSP's Total Operating Expenses and Operating Income been favorable recently?

Operational Expenses represent the costs a company must incur to generate revenue, which is the ultimate goal of a business, whereas Operating Income shows the revenue left after operational direct and indirect costs have been deducted. CRSP incurred $99.58M worth of Operating Expenses, while it generated -$110.13M worth of Operating Income.

How much Net Income has CRSP posted recently?

The Net Income of a company is one of the factors investors consider when investing in the company. According to recent earnings report from CRISPR Therapeutics AG, the company generated -$85.94M in Net Income. When a company has a history of consistent net income, investors are more likely to invest in it since they know they will get a return.

At the end of the last quarter, how much Cash and Equivalents did CRISPR Therapeutics AG have?

The amount of Cash and Cash Equivalents is an effective indicator of the financial strength and well-being of a company. An excess cash situation occurs when a company has more cash and cash equivalents than it needs for operating activities. The amount of Cash and Cash Equivalents available to CRISPR Therapeutics AG as of the end of the last quarter was $225.67M.

What are CRSP's Total Net Receivables for the last quarter?

Total Net Receivables are a company's outstanding debts to its customers. Therefore, it refers to the amount that a company expects to collect from its customers. The higher a company's net receivables are, the more confident it is that it can collect money from its debtors. As of the end of the last quarter, CRSP had Total Net Receivables of $0.00.

In terms of Total Assets and Current Assets, where did CRISPR Therapeutics AG stand at?

An asset with an economic value within a year is considered a current asset. Total assets, however, also include long-term fixed assets, intangible assets, and other non-current assets. The current Assets of CRSP were $1.94B, while the Total Assets stand at $2.26B.

As of the last quarter, how much Total Debt did CRISPR Therapeutics AG have?

The total debt of a business refers to how much it borrows. A company's current and long-term liabilities are added together to calculate its Total Debt. A debt ratio may be taken into account on a balance sheet by financial lenders, investors, and business leaders when making informed decisions about future loans or investments. The total amount of CRSP's debt was $227.55M at the end of the last quarter.

What were CRSP's Total Liabilities during the last reported quarter?

A company's total liabilities are the sum of all debts it is liable for, including any off-balance shee liabilities it may incur. This can be calculated by adding up all short-term and long-term liabilities. In its last quarter, CRSP reported total liabilities of $316.47M.

How much did CRSP's Working Capital change over the last quarter?

Working Capital Change for CRSP was -$220.98M over the last quarter. Working Capital Change refers to the difference between net working capital amounts at the end of one accounting period and the end of another. It tells investors/stakeholders how much the company's cash flow will differ from its Net Income (i.e., after-tax profits). More powerful companies often have positive Change in Working Capital numbers as they have increased control over collecting cash from customers and delaying payments to suppliers.

CRSP generated how much cash from operating activities?

An operating cash flow statement usually contains cash from operating activities in the first section. An organization's cash from operating activities refers to the money it takes in and takes out as a result of its regular business operations. CRSP generated -$106.91M of Cash from Operating Activities during its recently reported quarter.

What was CRSP's latest reported Net Change in Cash?

An increase or decrease in cash and cash equivalent balances within a specified period is considered the net change in cash in a cash flow statement. Furthermore, it takes into account cash changes as a result of investments, financing, and operating activities. CRSP reported a -$247.28M Net Change in Cash in the most recent quarter.

logo

Stocks Telegraph provides information and tools designed to assist investors and Wall Street players. A major goal is to offer financiers comprehensive information that will help them gain insight into investing.

Stocks Telegraph does not provide any advice or recommendations for buying or selling stocks, securities, or other financial products. Information contained on this website is for informational purposes only and should not be construed as professional financial, investment or other advice. Stocks Telegraph is not liable for any loss or damage that may occur as a result of reliance on this data.

© 2025 Stocks Telegraph All rights reserved.
Most stock quote data provided by financialmodelingprep.com

stockstelegraph

Don't have an account?

stockstelegraph

Don't have an account?

stockstelegraph

Already have an account?

stockstelegraph
Smart Screening Tools for Exceptional Returns
stockstelegraph

For just $1, you can unlock ST Grading’s top-rated stocks that consistently beat the market. Our AI-powered Smart Screener finds winning trades in seconds, helping you uncover hidden opportunities before others do.

Ready to Win Big?

Try Now for Just $1!
stockstelegraph